7.1 Prescription Labeling Standards & Expiration / Beyond-Use Dating

7.1 Prescription Labeling Standards & Expiration / Beyond-Use Dating

[!NOTE] Dual Statutory Governance: Outpatient prescription labeling in Alabama is governed concurrently by the Alabama Pharmacy Practice Act (Code of Alabama 1975 § 34-23-9), Alabama State Board of Pharmacy (ALBOP) administrative rules (Ala. Admin. Code r. 680-X-2), the Federal Food, Drug, and Cosmetic Act (FDCA § 503(b)(2); 21 U.S.C. § 353), and the federal Controlled Substances Act (21 C.F.R. Part 1306 and 21 C.F.R. § 290.5). Candidates preparing for the Alabama MPJE must demonstrate mastery over mandatory state label elements, controlled substance warning annotations, and United States Pharmacopeia (USP) beyond-use dating standards.

A prescription label is the primary legal and clinical communication instrument linking the prescriber's therapeutic intent, the dispensing pharmacist's verification, and the patient's safe administration of medication. Dispensing a prescription drug in a container lacking any mandatory statutory label element constitutes misbranding under both federal and Alabama law, subjecting the dispensing pharmacist and the pharmacy permit holder to disciplinary sanctions and potential civil liability.

---

Mandatory Prescription Label Elements: Code of Alabama 1975 § 34-23-9

Under Ala. Code § 34-23-9, no person shall dispense any prescription drug or medicine unless the container in which it is dispensed bears a label displaying specific statutory items. While federal law sets minimum baseline exemptions under FDCA § 503(b)(2), Alabama state law imposes explicit, heightened labeling mandates that every practitioner must observe.

+-----------------------------------------------------------------------------------------+
|                   Alabama Statutory Prescription Label Checklist                        |
|                            (Ala. Code § 34-23-9)                                        |
+-----------------------------------------------------------------------------------------+
| 1. Pharmacy Name and Physical Street Address                                            |
| 2. Pharmacy Telephone Number (Mandatory Alabama Requirement)                            |
| 3. Serial Prescription Identification Number (Rx Number)                                |
| 4. Date of Original Dispensing or Date of Refilling                                     |
| 5. Full Legal Name of the Prescribing Practitioner                                      |
| 6. Full Name of the Patient (or Owner's Name and Species if Animal)                    |
| 7. Brand Name or Generic Drug Name Dispensed                                            |
| 8. Name of Drug Manufacturer or Distributor (Mandatory when Generic Dispensed)          |
| 9. Exact Strength and Dosage Form of the Medication                                     |
| 10. Clear, Specific Directions for Patient Use ("Sig") as Stated by Prescriber          |
| 11. Cautionary and Auxiliary Statements (e.g., "Shake Well", "Take with Food")         |
| 12. Beyond-Use Date (BUD) or Expiration Date                                            |
+-----------------------------------------------------------------------------------------+

1. Pharmacy Identifiers & The Telephone Number Mandate

The label must bear the legal business name and physical practice address of the dispensing pharmacy. A critical point frequently tested on the Alabama MPJE is that Alabama law explicitly requires the pharmacy's telephone number to be printed on the prescription label. Omitting the pharmacy's telephone number is a direct violation of state labeling statutes, even if the complete physical address appears.

2. Prescription Tracking & Dispensing Dates

The container must display the serial prescription number assigned by the dispensing pharmacy's management system. The label must also show the date the prescription is filled. When refilling a prescription, Alabama rules require indicating the refill date, and best practice documents both the original date of issuance and the current refill date to maintain audit trail transparency.

3. Patient and Prescriber Identifiers

The label must clearly state the full legal name of the patient. For veterinary prescriptions, the label must state the full legal name of the animal's owner and clearly specify the animal species (e.g., "John Doe (Canine)"). The full name and professional credential of the prescribing practitioner (e.g., "Dr. Robert Smith, M.D.") must appear.

4. Drug Identification: Generic Labeling & Manufacturer Disclosure

Under Ala. Code § 34-23-9, the label must identify the drug by its established name:

• If a brand-name drug is dispensed, the brand name must appear on the label.
• If a generic drug is substituted pursuant to Alabama's drug selection law (Ala. Code § 34-23-8), the label must display the generic name of the drug product AND the name of the manufacturer or distributor of the finished dosage form (e.g., "Amlodipine 5 mg Tablets, Mfg: Teva Pharmaceuticals"). In lieu of placing the manufacturer name directly on the label face, the pharmacy's electronic record system must maintain an immutable record of the manufacturer or distributor; however, placing the manufacturer directly on the label is the standard regulatory practice in Alabama.
• The label must state the precise metric strength (e.g., "10 mg", "250 mg/5 mL") and the quantity dispensed.

5. Directions for Patient Use & Auxiliary Warnings

The directions for use must be complete, precise, and unambiguous. Vague or open-ended phrases such as "take as directed" or "use as needed" do not satisfy statutory standards unless specifically accompanied by defined frequency limits (e.g., "Take 1 tablet by mouth every 6 hours as needed for severe pain"). Furthermore, appropriate cautionary auxiliary labels must be affixed where clinically indicated (e.g., drowsiness warnings, do not drink alcoholic beverages, finish all medication, protect from sunlight).

---

Federal Controlled Substance Labeling & Transfer Warnings

Prescriptions for controlled substances (Schedules II, III, IV, and V) are subject to heightened federal labeling standards under Title 21 of the Code of Federal Regulations (21 C.F.R. § 1306.14, 21 C.F.R. § 1306.24, and 21 C.F.R. § 290.5).

The Mandatory Federal Transfer Warning (21 C.F.R. § 290.5)

Under federal law, the container of every drug dispensed pursuant to a prescription for a controlled substance in Schedule II, Schedule III, or Schedule IV must bear a clear cautionary statement reading exactly:

"Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed."

+-----------------------------------------------------------------------------------------+
|                  Federal Transfer Warning Applicability Matrix                          |
|                              (21 C.F.R. § 290.5)                                        |
+-----------------------+-----------------------+-----------------------------------------+
| Controlled Schedule   | Warning Mandated?     | Legal Rationale / Scope                 |
+-----------------------+-----------------------+-----------------------------------------+
| Schedule II (C-II)    | YES (Mandatory)       | High potential for abuse/dependence     |
| Schedule III (C-III)  | YES (Mandatory)       | Moderate potential for abuse/dependence |
| Schedule IV (C-IV)    | YES (Mandatory)       | Lower potential for abuse/dependence    |
| Schedule V (C-V)      | NO (Statutorily Exempt)| Explicitly excluded under § 290.5       |
+-----------------------+-----------------------+-----------------------------------------+

[!CRITICAL] The Schedule V Statutory Exemption Trap: On the MPJE, candidates are frequently tested on whether the federal transfer warning is required on Schedule V drugs. Under federal regulation 21 C.F.R. § 290.5, the transfer warning statement is required ONLY on Schedules II, III, and IV. Schedule V controlled substances (such as pregabalin, lacosamide, or codeine cough syrups) are statutorily exempt from this federal transfer warning mandate. While many automated pharmacy management systems print this warning universally on all controlled substances as a safety precaution, federal law does NOT require it on Schedule V containers.

Narrow Institutional Labeling Exemptions (21 C.F.R. § 1306.14(b) & § 1306.24(b))

The detailed outpatient labeling requirements—including the federal transfer warning—do not apply when a controlled substance is dispensed for administration to an institutionalized inpatient (e.g., in a hospital or nursing home), provided that:

1. For Schedule II: Not more than a 7-day supply is dispensed at one time;
2. For Schedules III–V: Not more than a 34-day supply or 100 dosage units (whichever is less) is dispensed at one time;
3. The drug is not in the possession of the ultimate user prior to administration;
4. The institution maintains appropriate safeguards and records regarding administration, control, and storage; and
5. The pharmacy system can identify the supplier, product, patient, directions, and cautionary warnings.

---

Expiration Date vs. Beyond-Use Date (BUD)

A fundamental legal and pharmaceutical distinction exists between a commercial drug manufacturer's expiration date and a dispensing pharmacist's beyond-use date (BUD). Confusing these two concepts is a frequent source of examination errors.

+-----------------------------------------------------------------------------------------+
|                     Manufacturer Expiration Date vs. Beyond-Use Date                    |
+------------------------------------+----------------------------------------------------+
| Manufacturer Expiration Date       | Beyond-Use Date (BUD)                              |
+------------------------------------+----------------------------------------------------+
| Determined by the drug manufacturer| Determined by the dispensing pharmacist            |
| Based on extensive stability tests | Based on repackaging, reconstitution, or container |
| Applies to sealed original container| Applies to the specific patient dispensing vial    |
| Guaranteed potency (typically ≥90%)| Date beyond which medication should not be used    |
| Stated in month/year or day/month/yr| Stated as specific day/month/year on label         |
+------------------------------------+----------------------------------------------------+

Interpreting Manufacturer Expiration Dates

When a commercial stock bottle displays an expiration date consisting solely of a month and year (e.g., "Exp: 09/2027"), federal FDA standards dictate that the drug remains stable, potent, and legally fit for dispensing through the very last day of that stated month (i.e., September 30, 2027). A drug cannot be dispensed on or after October 1, 2027.

The USP <659> & <795> Beyond-Use Dating Standards for Amber Vials

When a pharmacist removes a solid or liquid medication from the manufacturer's original bulk container and packages it into a multiple-unit outpatient container (such as a standard amber plastic prescription vial), the original stability parameters no longer apply because the closure has been breached and the medication is exposed to ambient atmospheric moisture and oxygen.

Under United States Pharmacopeia standards (USP General Chapter <659> Packaging and Storage Requirements and USP <795>):

• The maximum allowable Beyond-Use Date (BUD) for non-sterile solid and liquid oral dosage forms repackaged into multiple-unit containers is:

$\text{BUD} = \min\Big(\text{Dispensing Date} + 1\text{ Year},\; \text{Manufacturer Stated Expiration Date}\Big)$

[!WARNING] The One-Year Rule Applied: If a pharmacist dispenses metformin tablets into an amber vial on September 6, 2026, and the manufacturer stock bottle expires in August 2028 (two years away), the maximum legal BUD that may be placed on the prescription label is September 6, 2027 (one year from dispensing). Conversely, if the manufacturer stock bottle expires on December 31, 2026 (less than one year away), the BUD on the patient's label can be no later than December 31, 2026. The label BUD can never exceed the manufacturer's stated expiration date.

---

Repackaged Unit-Dose Packaging Requirements

Unit-dose packaging involves packaging a single dosage form (such as one tablet or capsule) in a hermetically sealed blister or pouch intended for direct administration to a patient without further manipulation.

Labeling Standards for Unit-Dose Products

Under federal FDA guidelines and Alabama practice rules, every individual unit-dose package must bear a label containing:

1. Established drug name (brand or generic);
2. Quantity of the active ingredient per single unit (strength);
3. Name and address of the manufacturer, packer, or distributor;
4. Lot or control number assigned by the manufacturer or repackager;
5. Expiration date or Beyond-Use Date (BUD);
6. Any special storage instructions (e.g., "Refrigerate", "Protect from light"); and
7. Controlled substance schedule symbol (if applicable).

USP Unit-Dose Beyond-Use Dating (The 25% Rule)

Under USP guidelines and FDA repackaging compliance policies for non-sterile solid oral dosage forms repackaged into unit-dose containers (such as heat-sealed unit-dose blisters):

• The BUD must not exceed one (1) year from the date of repackaging, OR
• 25% of the remaining time between the repackaging date and the manufacturer's bulk expiration date, whichever is shorter!
• Example: If a pharmacist repackages bulk capsules into unit-dose blister strips on January 1, 2026, and the bulk manufacturer container expires on January 1, 2027 (12 months remaining), 25% of the remaining 12 months is 3 months. The assigned BUD cannot exceed April 1, 2026 (3 months from repackaging), because 3 months is shorter than 1 year.

---

Customized Patient Medication Packages: Multi-Dose Med-Paks

A customized patient medication package (Med-Pak) is a multi-compartment container prepared by a pharmacist for a specific patient, containing two or more prescribed solid oral dosage forms organized by day and time of administration (e.g., morning, noon, evening, bedtime blister systems) to enhance patient adherence.

+-----------------------------------------------------------------------------------------+
|                        Customized Med-Pak Packaging Checklist                           |
|                                  (USP Standards)                                        |
+-----------------------------------------------------------------------------------------+
| • Multi-dose compliance blister containing ≥ 2 solid oral dosage forms                  |
| • Individual serial number for the Med-Pak itself PLUS separate Rx number for each drug |
| • Identification of each drug: Name, strength, physical description, and total quantity|
| • Patient full legal name and complete directions for use for each medication           |
| • Storage instructions, cautionary auxiliary warnings, and dispenser identifiers        |
| • MAXIMUM BEYOND-USE DATE: 60 Days from preparation (or earliest manufacturer expiry)   |
+-----------------------------------------------------------------------------------------+

Med-Pak Mandatory Labeling Elements

Because a Med-Pak combines different pharmaceutical agents into single blister cavities, it is subject to rigorous labeling standards. Under USP guidelines and Alabama Board standards, the Med-Pak label must include:

1. The full legal name of the patient;
2. A unique serial identification number for the Med-Pak package itself, PLUS the separate serial prescription number for each individual drug order contained within;
3. The name, strength, physical description (e.g., color, shape, scoring, debossed imprint code), and total quantity of each drug product;
4. Clear, comprehensive directions for use, including the specific time of day each compartment is to be opened;
5. Any cautionary auxiliary statements applicable to each individual drug;
6. Special storage instructions;
7. The name, address, and telephone number of the dispensing pharmacy;
8. The full name of the prescribing practitioner for each medication; and
9. The Beyond-Use Date assigned to the customized package.

The 60-Day Med-Pak Beyond-Use Date Ceiling

$\text{Med-Pak BUD} = \min\Big(60\text{ Days from Date of Preparation},\; \text{Earliest Manufacturer Expiry of Any Component}\Big)$

[!CRITICAL] Strict 60-Day Regulatory Limit: Under USP standards, the maximum allowable Beyond-Use Date that can ever be assigned to a customized patient medication package (Med-Pak) is sixty (60) days from the date of preparation, or the earliest manufacturer expiration date of any individual drug included in the Med-Pak, whichever is shorter. Candidates must never assign a 1-year BUD to a Med-Pak. If one drug in the pack expires in 40 days, the BUD for the entire Med-Pak becomes 40 days.

---

Outpatient Packaging & Dating Standards Comparison Matrix